SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Vertex Pharmaceuticals Incorporated Presents New Phase 3 Data that Showed People With Hepatitis C Treated With Twice-Daily Telaprevir Achieved Viral Cure (SVR12) Rates Similar to Those Treated Three Times Daily